Recent Updates — SRZNW
Surrozen completed the second and final closing of its March 2025 private placement, generating approximately $95.1 million in gross proceeds. The transaction was contingent upon FDA clearance of the Investigational New Drug application for SZN-8141, which occurred on October 2, 2026. The company issued 5,741,605 shares of common stock, pre-funded warrants to purchase 2,456,500 shares, and Series E common stock warrants to purchase 4,099,052 shares at a price of $11.60 per share. Proceeds will strengthen the balance sheet and provide cash runway into 2029 to advance clinical development of SZN-8141 and SZN-8143. Surrozen is a biotechnology company pioneering Wnt-based therapeutics for sight-threatening ophthalmic conditions.
Surrozen announced FDA clearance of the Investigational New Drug application for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody for diabetic macular edema. This regulatory milestone triggers the second closing of its March 2025 private placement, expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026. The company plans to dose the first patient in the DUET Phase 1b/2a study in Q4 2026, with initial data anticipated in H2 2027. Surrozen will file a Form S-3 registration statement within 30 days of closing to register resale of issued securities. The company operates in the biotechnology industry, developing therapies for retinal diseases.
Surrozen reported second quarter 2026 results with $5.0 million in collaboration revenue from Boehringer Ingelheim and a net income of $50.2 million, driven by non-cash gains on warrant and tranche liabilities. The company announced plans to submit an IND application for its lead candidate SZN-8141 by the end of Q3 2026 and initiate the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026, with initial data expected in H2 2027. Additionally, the U.S. PTAB denied Merck’s post-grant review petition challenging Surrozen’s patent No. 12,297,278. Surrozen operates as a biotechnology company developing Wnt-based therapeutics for sight-threatening ophthalmic conditions.